within Pharmacolibrary.Drugs.ATC.V;

model V08DA05
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 3.666666666666667e-06,
    adminDuration  = 600,
    adminMass      = 2.4 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0039,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0015,
    k12             = 0.21,
    k21             = 0.21
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>V08DA05</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Sulfur hexafluoride, phospholipid microspheres (marketed as SonoVue or Lumason) is an ultrasound contrast agent approved for use in echocardiography and selected radiology procedures. It is a suspension of sulfur hexafluoride gas encapsulated by phospholipid microspheres, used diagnostically to enhance the ultrasound imaging of blood vessels, cardiac chambers, and specific organs. The agent is currently approved and in clinical use in various regions.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after intravenous bolus administration.</p><h4>References</h4><ol><li><p>Correas, JM, et al., &amp; Hélénon, O (2001). Ultrasound contrast agents: properties, principles of action, tolerance, and artifacts. <i>European radiology</i> 11(8) 1316–1328. DOI:<a href=&quot;https://doi.org/10.1007/s003300100940&quot;>10.1007/s003300100940</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11519538/&quot;>https://pubmed.ncbi.nlm.nih.gov/11519538</a></p></li><li><p>Uller, W, et al., &amp; Jung, EM (2011). Evaluation of the microcirculation of hepatocellular carcinomas using contrast-enhanced ultrasound with intraarterial and intravenous contrast application during transarterial chemoembolization with drug-eluting beads (DEB-TACE): preliminary data. <i>Clinical hemorheology and microcirculation</i> 49(1-4) 55–66. DOI:<a href=&quot;https://doi.org/10.3233/CH-2011-1457&quot;>10.3233/CH-2011-1457</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/22214678/&quot;>https://pubmed.ncbi.nlm.nih.gov/22214678</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end V08DA05;
